What is larazotide designed to do?

It is studied as a gut tight-junction regulator (zonulin antagonist) intended to reduce intestinal permeability, often discussed in the context of celiac disease research.

Is it absorbed into the bloodstream?

No. It is designed to act locally within the intestinal lumen with minimal systemic absorption.

Is N-Acetyl Larazotide approved?

No. The parent peptide reached clinical trials but is not an approved drug, and the N-acetyl analog is sold strictly as a research compound.

← All peptides

Healing & Recovery

Immune

Research Chemical

N-Acetyl Larazotide

Also known as: N-Acetyl Larazotide, Larazotide

An N-acetylated analog of larazotide acetate, an octapeptide studied as a tight-junction regulator intended to reduce intestinal permeability (leaky gut). The N-acetyl modification is marketed to improve enzymatic stability of the parent peptide.

Mechanism of Action

Larazotide acts locally in the gut lumen as a zonulin antagonist, blocking the zonulin signaling pathway that loosens epithelial tight junctions. By inhibiting tight-junction disassembly it reduces paracellular passage of antigens such as gliadin peptides across the intestinal barrier. It is not appreciably absorbed systemically, exerting effects at the apical surface of enterocytes. The acetylated derivative is proposed to resist brush-border peptidase degradation longer than the parent compound.

Half-life: Very short systemic half-life (acts locally in the gut lumen)
Administration Routes: oral
Research Status: Research Chemical